Jason T. Olin
Forest Research Institute
6 Papers
14 Citations
Jason T. Olin is an academic researcher from Forest Research Institute. The author has contributed to research in topics: Memantine & Clinical trial. The author has an hindex of 5, co-authored 6 publications.
Chat about Author
Papers
Memantine Treatment in Mild to Moderate Alzheimer Disease: A 24-Week Randomized, Controlled Trial
Elaine R. Peskind,Steven G. Potkin,Nunzio Pomara,Brian R. Ott,Stephen M. Graham,Jason T. Olin,Scott D. McDonald +6 more
TL;DR: In this paper, the authors compared the efficacy and safety of the moderate affinity, uncompetitive N-methyl-d-aspartate receptor antagonist, memantine, versus placebo in patients with mild to moderate Alzheimer disease (AD).
322
Potential ethnic modifiers in the assessment and treatment of Alzheimer's disease: challenges for the future.
Warachal Faison,Susan K. Schultz,Jeroen Aerssens,Jennifer Alvidrez,Ravi Anand,Lindsay A. Farrer,Lissy F. Jarvik,Jennifer J. Manly,Thomas McRae,Greer M. Murphy,Jason T. Olin,Darrel A. Regier,Mary Sano,Jacobo Mintzer +13 more
TL;DR: Greater participation of ethnically diverse participants in clinical trials for AD would generate additional information on possible differences in metabolism, treatment response, adverse events to therapeutic agents, and could foster the investigation of genetic variability among ethnic groups.
72
Hydergine for dementia.
TL;DR: Hydergine was found to show significant treatment effects when assessed by either global ratings or comprehensive rating scales, and to investigate potential moderators of an effect.
53
Meta-analysis of 6-month memantine clinical trials in Alzheimer’s disease
Rachelle S. Doody,Pierre N. Tariot,Eric Pfeiffer,Jason T. Olin,Stephen M. Graham,Joanne M. Bell +5 more
TL;DR: The results demonstrate that pharmacological blocking of the apoE/A interaction may be used to prevent A deposition in AD patients.
10